Immunotoxins are conjugates of antibodies, or antibody fragments, with protein toxins, usually of plant or bacterial origin. Several recent reviews have been published which cover the background to and potential use of immunotoxins Fitzgerald & Pastan, 1989; Vitteta & Thorpe, 1991; Wawrzynczak, 1991) . In recent years, much research has been undertaken in an attempt to perfect immunotoxins for clinical use and, of those evaluated in the clinic, most have incorporated ricin A-chain as the toxin. This plant toxin is a potent inhibitor of protein synthesis which acts by catalytically removing an adenine moiety from the 28S ribosomal subunit . The original ricin A-chain conjugates that were developed utilised native, plant-derived, ricin A-chain and this was found to be responsible, in part, for the rapid plasma clearance of the immunoconjugate. Rapid clearance is due to hepatic recognition of carbohydrate residues that are abundantly present on native ricin A-chain (Blakey & Thorpe, 1986; Bourrie et al., 1986; Byers et al., 1987) . Use of a deglycosyl or aglycosyl toxin substantially reduces initial immunotoxin clearance from the plasma without compromising cytotoxic potency (Blakey et al., 1987; Trown et al., 1991; Wawrzynczak et al., 1990; 1991a; 1991b) .
The second factor influencing immunotoxin peristence in vivo is the stability of the disulphide bond linking the toxin and the antibody. Rapid in vivo cleavage of an immunotoxin is disadvantageous both because it reduces the duration of tumour cell exposure to active agent and because the free antibody released can theoretically compete with immunotoxin for binding to the target antigen. Steric hindrance of the disulphide bond produces stabilisation of the conjugate to reduction by free thiols, for example glutathione, which results in a prolongation of the P-phase of immunotoxin pharmacokinetics, without reducing antigen binding or toxin potency (Thorpe et Worrell et al., 1986) . Data generated by pharmacokinetic modelling have shown that, for good immunotoxin or antibody tumour penetration, a long plasma half life may be at least as beneficial as a high antigen density or antibody binding affinity (Fujimori et al., 1989; Sung et al., 1990) .
Several immunotoxins have entered into clinical studies (Byers et al., 1989; Gould et al., 1989; Hertler et al., 1988; Pai et al., 1991; Spitler et al., 1987; Vitetta et al., 1991; Weiner et al., 1989) . However, success in patients has been disappointing. The problems that have been encountered include poor tumour specificity of the conjugate resulting in antibody-directed normal tissue toxicity (Gould et al., 1989; Pai et al., 1991) and immunotoxin-induced capillary leak syndrome, observed in nearly all studies. In addition, where acceptable patient tolerance of immunotoxins has been achieved, no consistent anti-tumour activity has been observed with the exception of a pan B-cell-directed ricin A-chain immunotoxin for the treatment of B-cell lymphoma (Vitetta et al., 1991) .
In the light of the above clinical and preclinical information, ICI D0490 has been conceived for the treatment of colorectal cancer. Aglycosyl recombinant ricin A-chain was selected as the toxin moiety, with the aim of reducing initial clearance, and a methyl-hindered disulphide coupling agent, N-succinimidyl 3-(2-pyridyldithio)-3-methylproprionate, was used with the aim of prolonging in vivo persistence. In the construction of ICI D0490 a tumour selective antibody, C242 (Larson et al., 1988; Kuusela et al., 1991) , was selected. This antibody shows binding to > 65% of the 200 colorectal tumour samples examined to date by immunoperoxidase staining (Wright et al., 1992) . The C242 antibody binds to the CA242 antigen (Baeckstrom et al., 1991) which is associated with the high molecular weight mucousglycoprotein CANAG (cancer-antigen). This paper reports the pharmacokinetic characteristics of ICI D0490 in non-tumour bearing mice after intravenous administration. These studies were performed in order to investigate whether or not the pharmacokinetic advantages anticipated by the use of a hindered disulphide linker and recombinant ricin A-chain had been achieved. The dose and schedule dependence of ICI D0490 pharmacokinetics have been investigated with a view to identifying, along with efficacy data, an optimal regime and dose escalation scheme for early clinical trials. Pharmacokinetics of ICI D0490 following iv administration To define the pharmacokinetics of ICI D0490 in detail, mice were dosed intravenously after briefly warming the tail in water at 45°C. A dose of 2.5 mg ICI D0490 kg-' in an injection volume of 0.1 ml g-' was administered and the time was recorded accurately. At 4, 7, 11, 17, 23, 29, 45 and 58 min, and 2, 3, 4, 8, 24, 48, 72 and 96 h thereafter, mice (four animals per group) were killed by CO2 asphyxiation, the thorax opened and a blood sample was taken directly from the left ventricle of the heart into syringes pre-rinsed with heparin (100 units ml -Iin saline). Plasma was prepared by centrifugation at room temperature and diluted 1:200 (v:v) directly into ELISA assay blocking buffer (see below).
Plasma concentrations of immunotoxin were quantified by an ELISA method (see below) and the concentration vs time data generated were analysed by both model-dependent and model-independent pharmacokinetic methods. The modeldependent method utilised a two compartment open model as described by the equation: Ct = Ae-' + Be-t where Ct is the plasma ICI D0490 concentration at time t, a and P are the first order rate constants for the first and second phases of plasma clearance and A and B are concentration constants. The equation was fitted to the data by non-linear least squares regression analysis using a weighting of I/Y2 (GraphPAD InPlot, GraphPAD Software, San Diego, USA). For the model-dependent analysis, microscopic rate constants, the volume of the central compartment (VI), volume of distribution at steady state (Vdss), clearance and area under the plasma concentration v. time curve (AUC) were calculated from the fitted values of A, a, B and P using standard equations (Welling, 1986 (1:10,000 dilution of material supplied by the manufacturer) added in blocking buffer for a 4 h incubation period at room temperature. After a further wash cycle, the second layer antibody, rabbit anti-goat conjugated to horseradish peroxidase (1:3750 dilution) was added in 100 gil blocking buffer to each well for a further overnight incubation at room temperature. Finally, the colour reaction was initiated by addition of 100 pl of 1 mg ABTS ml-'in acetate buffer at pH 4.2 containing hydrogen peroxide (0.013%, v/v). When the standard equivalent to 1.6 pg ICI D0490 ml' in plasma reached an optical density of 0.7 at 405 nm, the reaction was stopped by the addition of 100 tl 1O mM aqueous sodium azide to each well and the plates read on a Dynatech MR7000 plate reader at 405 nm. Standard curves equivalent to 0.05 to 25 iLgICI D0490 ml-' plasma were generated using a 5-parameter fit available on MULTICALC software (Wallac Oy, Software), and values calculated for unknown samples, each of which was analysed in triplicate. During the experiments described in the present paper, 'within day' and 'between day' coefficients of variation for quality assurance samples at 0.5 lAg ICI D0490 ml' plasma were <5% and 8%, respectively. The assay was most precise in the midrange of the standard curve and consequently values were only used from this region. Plasma samples were diluted in series to ensure that a value in the accurate range of the curve was obtained.
Results
Preliminary toxicity studies Mice received a single iv bolus dose of ICI D0490 and were monitored for signs of toxicity. Adverse effects were manifested as body weight loss and hypokinesia. The LDIO was defined as a single dose of 5.4 mg kg-' (95% limits 4.9-5.8 mg kg-'). The lethal toxicity was delayed for about three days after dosing which enabled a single dose of 5 mg kg' to be safely administered for characterisation of initial plasma levels of ICI D0490. For longer time points, 50% of the LDIO (2.5 mg kg-') was the maximum dose studied.
Pharmacokinetics of ICI D0490 following i.v. administration
After a single intravenous dose of 2.5 mg kg', ICI D0490 could be detected in the plasma of mice at all of the time points studied from 4 min to 96 h (Figure 1 ). The AUC, clearance and volume of distribution were calculated from the data using model-independent calculations and these values were compared to the values obtained when the data were fitted to a two compartment open model, ( Table I) . The model-dependent and independent analyses gave comparable results and hence the use of a two compartment model is appropriate. Notably, the clearance of ICI D0490 from the plasma was extremely slow (34 psl min-kg-') and the P- Thus, the contribution of the a-phase to total ICI D0490 AUC can be calculated as A/a. The value so obtained, 3.9 mg ml-' min-', in comparison to the total AUC, 73 mg ml-' min-' (Table I) Figure 2 , there was a good correlation between ICI D0490 dose and plasma concentrations at both time points and the slope of the relationships, when both concentration and dose data were logarithmically transformed, was unity (2 h = 0.99 ± 0.04; 24 h = 1.02 ± 0.07, mean ± SE). ICI D0490 could only be detected at 2 h following doses of 0.005 and 0.01 mg kg-'. Hence the data obtained from this study indicate that the pharmacokinetics of ICI D0490 are linearly related to dose over at least a 100-fold range of doses from 0.05 mg kg-' to Smgkg-'.
Effect of repeated administration on the plasma levels of ICI
D0490
To investigate possible alterations in ICI D0490 clearance following repeated administration, a single iv bolus dose of 5mgkg-' was compared to 1mgkg' day-' x 5 and 1.67 mg kg-' given on days 1, 3 and 5. As shown in Table II, no accumulation of ICI D0490 in the plasma over the period studied was seen at these dose levels. This is surprising since following a single dose of 2.5 mg kg-' the concentration of ICI D0490 in the plasma at 24 h (15 fg ml-') was 37% of the extrapolated concentration at time zero (Figure 1 ). Normalising the data to a dose of 1 mg kg-', this is equivalent to 5.6 ytg ml-' which is within the observed range of ICI D0490 plasma levels 24 h after the first dose of 1 mg kg-' (6.3 ± 2.6 jig ml1', Table II ). However, on repeated dosing at 1 mg kg' no accumulation of ICI D0490 was observed. If anything, 2 h plasma levels appear to be lower following repeated administration of ICI D0490 (Table II) . Taken together, the lack of ICI D0490 accumulation over 5 days and the apparent decrease in plasma levels at 2 h suggests that plasma clearance of the immunotoxin may be induced by repeated administration.
Discussion
The experiments reported here show that ICI D0490 has favourable pharmacokinetic properties when administered intravenously to mice. Following a single iv dose of 2.5 mg ICI D0490 kg-plasma levels could be fitted to a two compartment open model without distortion of the data. There was little initial clearance from the plasma and a relatively long ox-phase half-life was observed. The volume of the central compartment approximates to that of the plasma volume in mice and hence during the initial 2 h period there is very little distribution of ICI D0490 from the plasma. In the light of earlier studies, the reduced initial clearance of ICI D0490 is probably a reflection of the aglycosyl nature of the recombinant ricin A-chain moiety of the immunotoxin (Thorpe et al., 1988; Trown et al., 1991; Wawrzynczak et al., 1991b) . The second notable feature of the pharmacokinetics of ICI D0490 is the long elimination phase half-life of 33 h. To our knowledge, this is the longest P-phase half life so far reported for an immunotoxin in rodents and this property is presumably a reflection of the stable disulphide linker moiety of the ICI D0490. This is consistent with the findings of Thorpe and colleagues who demonstrated that, whilst the a-phase half life and plasma clearance were heavily influenced by A-chain glycosylation, the P-phase half life is a function of steric hindrance to cleavage of the disulphide bond (Thorpe et al., 1988) . Similar results were obtained by Worrell et al. (1986) and these latter authors developed the methyl-hindered linker used in the construction of ICI D0490. The potential importance of a long P-phase half life for immunotoxins has recently been underlined by modelling studies which suggest that half life can be an important as antibody binding affinity as a determinant of tumour localisation (Sung et al., 1990) . Furthermore, in their preclinical study, Thorpe et al. (1988) Following a dose of 50% of the LDIo, the plasma levels of ICI D0490 were sustained at over 20 jig ml-' for 8 h and at over 1 jg ml-' for 96 h (Figure 1 ). This latter concentration is in excess of the level required in vitro to produce greater than 99.9% cell kill in a clonogenic assay using either CoLo201 or CoLo2O5 human colorectal tumour cells. Furthermore, 2.5 mg ICI D0490 kg-' is a dose that gives long growth delays (> 30 days) in a nude mouse xenograft model with the CoLo201 tumour that expresses the CA242 antigen (J. Calvete, unpublished results). However, no anti-tumour activity with this dose of ICI D0490 was observed against xenograft tumours not expressing CA242 antigen.
When a wide range of single doses of ICI D0490 was studied it was evident that there was a linear relationship between the dose given and plasma levels achieved, at 2 and 24h, time points that reflect both phases of immunotoxin clearance. Thus, the pharmacokinetics of a low dose of ICI D0490 should allow the prediction of doses required to achieve target plasma levels. Dose escalation in early clinical trials, on the basis of plasma level data, has been widely advocated for cytotoxic drugs (Newell, 1990 ) although the role of this approach in studies with immunotoxins remains unclear. Given the limitations of preclinical toxicity models, initial doses of immunotoxins in Phase I trials should be conservative. However, once initial safety is established, dose escalation should be performed as quickly as possible. With an understanding of the immunotoxin concentrations required for in vitro cytotoxicy, and the plasma levels seen in mice following administration of therapeutic doses, it may be possible to guide dose escalation in patients. Whilst attractive, pharmacokinetically-guided dose escalation can only be attempted if a linear relationship exists between dose given and plasma level achieved. On the basis of the results presented in Figure 2 , the pharmacokinetics of ICI D0490 would appear to be linearly related to dose and hence pharmacokinetics monitoring will be performed as part of the Phase I trial of the drug with a view to guiding dose escalation. An important aspect of pharmacokinetically-guided dosing is that pre-clinical and clinical studies should be comparable in terms of route and schedule. Initial phase I studies with ICI D0490 will involve single dose intravenous bolus administration.
In conclusion, these pharmacokinetic studies with ICI D0490 have shown it to be an extremely stable immunotoxin. Parallel pre-clinical studies, in the rat and a primate, support this conclusion (Dr J. Lynch, personal communication 
